Evaluation of effect of newer antiepileptic drugs (Lamotrigine and Zonisamide) on cognitive performance in patients of epilepsy.
Keywords:
Lamotrigine, Zonisamide, Cognition, Epilepsy.Abstract
Introduction: Epilepsy, a disorder of unprovoked seizures is a multifaceted disease affecting individuals of all ages with a particular predilection for the very young and old. Epilepsy is one of the most common neurologic conditions, with an incidence of approximately 50 new cases per year per 100,000 population. Impairment in cognitive function is a major influential factor on drug tolerability. Hence, we aimed at evaluating the effect of newer antiepileptic medicines (Lamotrigine and Zonisamide) on cognitive functions in patients who were seizure free for one year, in Western India.
Material & Methods: It was a prospective observational cohort study. Patients receiving newer antiepileptic medicines as monotherapy and satisfying the inclusion and exclusion criteria were included in this study. Evaluation of cognitive performance was done by using Addenbrooke’s Cognitive Examination Revised [ACER] Questionnaire at baseline followed by three months and six months.
Observation and Results: Out of 51 enrolled patients, 39 completed the study. Newer AEDs Lamotrigine and Zonisamide had shown positive outcome on the cognitive performance for the parameters of attention, concentration, memory, verbal fluency, language and visuospatial skills.
Conclusion: As concluded by previous studies, it has been established that newer antiepileptic drugs like Lamotrigine and Zonisamide definitely improves baseline cognitive performance score. Further comparative studies with older antiepileptic drugs (AEDs) are needed to establish higher level of evidence.
Downloads
References
Joseph I. Sirven. Epilepsy: A Spectrum Disorder. Cold Spring Harb Perspect Med 2015 May:a022848.
Carl E. Stafstrom and Lionel Carmant. Seizures and Epilepsy: An Overview. Cold Spring Harb Perspect Med 2015;May:a022426.
Eddy CM, Rickards HE, Cavanna AE. Behavioral adverse effects of antiepileptic drugs in epilepsy. J Clin Psychopharmacol. 2012 Jun; 32 (3):362-75.
Eddy CM, Rickards HE, Cavanna AE. The cognitive impact of antiepileptic drugs. Ther Adv Neurol Disord. 2011 Nov; 4(6):385-407.
French JA, Staley BA. AED Treatment Through Different Ages: As Our Brains Change, Should Our Drug Choices Also? Epilepsy Curr. 2012 Jul; 12(Suppl 3):22-7.
Cramer JA, Mintzer S, Wheless J, Mattson RH. Adverse effects of antiepileptic drugs: a brief overview of important issues. Expert Rev Neurother. 2010 Jun; 10(6):885-91.
Ijff DM, Aldenkamp AP. Cognitive side-effects of antiepileptic drugs in children. Handb Clin Neurol. 2013; 111:707-18.
Cavanna AE, Ali F, Rickards HE, McCorry D. Behavioral and cognitive effects of anti-epileptic drugs. Discov Med. 2010 Feb; 9(45):138-44.
Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, Clark PO, Adamson PC; Childhood Absence Epilepsy Study Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia. 2013 Jan; 54(1): 141-55.
Eun SH, Kim HD, Eun BL, Lee IK, Chung HJ, Kim JS, Kang HC, Lee YM, Suh ES, Kim DW, Eom S, Lee JS, Moon HK. Comparative trial of low- and high-dose Zonisamide as monotherapy for childhood epilepsy. Seizure. 2011 Sep; 20(7): 558-63.
Pavuluri MN, Passarotti AM, Mohammed T, Carbray JA, Sweeney JA. Enhanced working and verbal memory after Lamotrigine treatment in pediatric bipolar disorder. Bipolar Disord. 2010 March; 12(2): 213–220.
Berent S, Sackellares JC, Giordani B, Wagner JG, Donofrio PD, Abou-Khalil B. Zonisamide (CI-912) and cognition: results from preliminary study. Epilepsia. 1987 Jan-Feb; 28(1):61-7.
Daban C, Martínez-Arán A, Torrent C, Sánchez-Moreno J, Goikolea JM, Benabarre A, Comes M, Colom F, Vieta E. Cognitive functioning in bipolar patients receiving Lamotrigine: preliminary results. J Clin Psychopharmacol. 2006 Apr; 26(2): 178-81.
Meador KJ, Baker GA, Browning N, Cohen MJ, Clayton-Smith J, Kalayjian LA, Kanner A, Liporace JD, Pennell PB, Privitera M, Loring DW; NEAD Study Group. Foetal antiepileptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain. 2011 Feb; 134(Pt 2): 396-404.
Makatsori A, Duncko R, Moncek F, Loder I, Katina S, Jezova D. Modulation of neuroendocrine response and non-verbal behavior during psychosocial stress in healthy volunteers by the glutamate release-inhibiting drug Lamotrigine. Neuroendocrinology. 2004 Jan; 79(1): 34-42.
Mills KC, Drazkowski JF, Hammer AE, Caldwell PT, Kustra RP, Blum DE. Relative influences of adjunctive topiramate and adjunctive Lamotrigine on scanning and the effective field of view. Epilepsy Res. 2008 Feb; 78(2-3):140-6. Epub 2007 Dec 21. Erratum in: Epilepsy Res. 2009 Sep; 86(1):99.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 International Journal of Pharmacological Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- Author must Submit Copyright form After acceptance of Article